|26th January 2021||Inc. Innoviva,||1,867,912||Open or private purchase||$3.25||$6,070,714.00|
|15th January 2021||Manoussos Perros||79,750||Grant/award etc.||$0.00|
|15th January 2021||Matthew Ronsheim||25,000||Grant/award etc.||$0.00|
|15th January 2021||John Patrick Mueller||25,000||Grant/award etc.||$0.00|
|15th January 2021||Elizabeth M Keiley||25,000||Grant/award etc.||$0.00|
|15th January 2021||David Altarac||25,000||Grant/award etc.||$0.00|
|1st September 2020||Inc. Innoviva,||4,672,897||Open or private purchase||$2.68||$12,499,999.48|
|11th June 2020||Inc. Innoviva,||12,677,490||Open or private purchase||$2.50||$31,693,725.00|
|27th March 2020||Inc. Innoviva,||7,717,661||Open or private purchase||$2.87||$22,149,687.07|
|4th February 2020||Life Sciences Viii, L.P. Frazier||6,360,272||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.